RxDoctor Payments Data

Nicole Soto, MD

Dermatology · Bismarck, NDNPI 1952383226

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,090 of the $3,642 with a category attached, or 84.8%. 18 manufacturers reported payments, led by AbbVie at 27.1% of the total. 2025 is the largest year on record at $1,161, more than ten times the $61 reported in 2019.

$3,642in general payments, 2019–2025

Across 177 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$987
  • E.r. Squibb & Sons, L.L.C.$397
  • Regeneron Healthcare Solutions, Inc.$390
  • Johnson & Johnson$358
  • Lilly USA, LLC$271
  • Incyte Corporation$251
  • plus $988 from 12 others

What the payments were for

  • Food & beverage$3,09085%
  • Education$55215%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,642 in reported general payments places this provider in the 75th percentile of 29 dermatology providers in North Dakota.

See all dermatology providers in North Dakota

Medicare billing

Part B allowed, 2024
$82,815
Medicare patients
483
Services billed
1,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab14$104,369
RinvoqUpadacitinib13$82,294
Tacrolimus43$5,870
Fluorouracil66$4,460
Clobetasol Propionate90$3,355
Ketoconazole125$2,747
Metronidazole53$2,055
Fluocinonide44$2,024
Mycophenolate Mofetil35$1,261
Triamcinolone Acetonide61$1,059
Fluconazole31$1,046
Imiquimod16$869
Hydrocortisone71$816
Tretinoin12$785
Clindamycin Phosphate15$726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$987$82,29413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 29 dermatology providers in North Dakota.

Other dermatology in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →